Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United States only.

Pentacel Banner

HELPING PROTECT KIDS IS A FULL-TIME JOB AND PENTACEL IS UP TO THE TASK

Let’s work together and help protect kids against potentially deadly diseases with the DTaP-IPV/Hib vaccine.1

INDICATION FOR PENTACEL

Pentacel is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Pentacel is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to 5th birthday).

START WITH PENTACEL

Start your primary DTaP immunization series in children 6 weeks through 4 years of age (prior to 5th birthday) with 4 doses of Pentacel, the only DTaP-IPV-Hib combination vaccine.1

Pentacel® mascot dressed as a doctor

Even if you didn’t use Pentacel for the first 3 doses, you can use it for the fourth dose

of the DTaP series containing the same pertussis antigens as in Pentacel.1*

*Data are not available on the safety and effectiveness of using mixed sequences of Pentacel and DTaP vaccine from different manufacturers.

illustration of a kid dressed for scuba

Pentacel may simplify vaccine administration by supporting A VACCINATION SCHEDULE WITH FEWER INJECTIONS compared to single-entity alternatives1-3

Centers for Disease Control and Prevention schedule through 6 years of age2

Adapted from: Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. 

aEven if you didn't use Pentacel for the first 3 doses, you can use it for the fourth dose of the DTaP series containing the same pertussis antigens as in Pentacel.1,d

Vaccination schedules may vary based on patients’ overall health status.1

bDepending on the type of vaccine used, a 3rd dose may be required.
cFor certain high-risk groups, a dose at 6-11 months of age is recommended.
dData are not available on the safety and effectiveness of using mixed sequences of Pentacel and DTaP vaccine from different manufacturers.

Illustration of handshake

Our journey and promise continue


Thank you for continuing to trust Pentacel for your primary DTaP immunization.1 We remain committed to helping you and your patients. Together, Sanofi’s promise to help protect stands strong.

efficiency icon

Data that demonstrate protection


Know that with Pentacel, your patients’ protection is backed by data. Pentacel has been evaluated in 4 clinical trials, and safety was demonstrated consistently.1

timelines icon

Approved by the FDA


Pentacel is the only FDA-approved, 4-dose DTaP combination vaccine.1,2

Your commitment to Pentacel gives your patients access to complete the recommended schedule.

Down arrow

Nationally, between 2019 and 2020, there was a drop-off of vaccination for the fourth dose of DTaP and Hib. The 13% drop-off for DTaP and 14% drop off for Hib could put patients at risk for disease4

bottle with number 4 on it

Even if you didn’t use Pentacel for the first 3 doses, you can use it for the 4th dose of the DTaP series, containing the same pertussis antigens as in Pentacel1*

*Data are not available on the safety and effectiveness of using mixed sequences of Pentacel and DTaP vaccine from different manufacturers.

illustration of shield

Continuing to choose Pentacel for the 4th dose helps your patients receive the protection that Pentacel has to offer1,2,4

illustration of hands

Parents and kids count on you. You can keep counting on us.

illustration of a kid dressed as am astronaut
Pentacel® provides immunization against DTaP, IPV & Hib for your pediatric patients. Learn about their continuity of antigen, immunization schedule & combination vaccines. Please read Important Safety Information and Prescribing Information.

IMPORTANT SAFETY INFORMATION FOR PENTACEL

Contraindications to vaccination with Pentacel include: a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Pentacel, or any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine, any ingredient of Pentacel; encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Pentacel to persons with a history of: fever ≥105°F not attributable to another identifiable cause, hypotonic-hyporesponsive episode within 48 hours, or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures with or without fever within 3 days after a previous pertussis antigen-containing vaccine; or adverse events after a previous dose of Pentacel or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following Pentacel.

For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with a vaccine containing acellular pertussis antigens (including Pentacel) and for the next 24 hours.

Individuals with altered immunocompetence, including individuals receiving immunosuppressive therapy, may have reduced immune responses to Pentacel.

Apnea following intramuscular vaccination has been observed in some infants born prematurely.

Syncope (fainting) may occur in association with administration of injectable vaccines including Pentacel. Procedures should be in place to avoid injury from fainting.

Vaccination with Pentacel may not protect all individuals.

The most frequent (>50% of participants) systemic reactions following any dose were fussiness/irritability and inconsolable crying. The most frequent (>30% of participants) injection site reactions following any dose were tenderness and increased circumference of the injected arm. Other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Pentacel (49281-0511-05).

CPT®e Code for Pentacel: 90698

Pentacel is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA, and distributed by Sanofi Pasteur Inc.

DTaP = diphtheria, tetanus, and acellular pertussis; Hib = Haemophilus influenzae type b; IPV = inactivated poliovirus; MMR = measles, mumps, and rubella; PCV = pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine; RV = rotavirus vaccine.

eCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

IMPORTANT SAFETY INFORMATION FOR PENTACEL

References: 1. Pentacel. Prescribing Information. Sanofi Pasteur Limited. 2. Centers for Disease Control and Prevention (CDC). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Accessed April 21, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 3. Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. Updated July 22, 2024. Accessed April 21, 2025. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf 4. Hill HA, Yankey D, Elam-Evans LD, Chen M, Singleton JA. Vaccination coverage by age 24 months among children born in 2019 and 2020 — National Immunization Survey-Child, United States, 2020–2022. MMWR Morb Mortal Wkly Rep. 2023;72(44):1190-1196.

MAT-US-2006087-v8.0-07/2025

Back to top
sanofi_campus_logo
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.